A Light-driven Electrochromic Materials-Based Nanomotor for H2S-Controlled Drug Release in Synergistic Cancer Chemotherapy Immunotherapy.

IF 16.1 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY
Luyan Wu, Xiang Cao, Yusuke Ishigaki, Qiang Tong, Fangqi Yang, Huihui Lin, Takanori Suzuki, Quli Fan
{"title":"A Light-driven Electrochromic Materials-Based Nanomotor for H2S-Controlled Drug Release in Synergistic Cancer Chemotherapy Immunotherapy.","authors":"Luyan Wu, Xiang Cao, Yusuke Ishigaki, Qiang Tong, Fangqi Yang, Huihui Lin, Takanori Suzuki, Quli Fan","doi":"10.1002/anie.202503297","DOIUrl":null,"url":null,"abstract":"Nanomotors hold tremendous potential for drug delivery. However, current nanomotors face limitations that compromise efficiency of drug utilization, including the use of inorganic materials with suboptimal soft interface and biocompatibility, uncontrollable drug release, insufficient directional control and slow movement speeds. Herein, we present a novel near-infrared (NIR) light-driven porous unsymmetric nanomotor with ultrafast motion, which utilizes hydrogen sulfide (H2S)-responsive cationic organic π-electron structure-based electrochromic material (F12+) for the payload and controlled release of anionic anticancer drugs, enabling synergistic cancer chemotherapy and immunotherapy. We demonstrate that the nanomotor can precisely target tumors driven by thermophoresis, tumor-targeting peptide (RGD) and H2S (highly expressed in tumors and acted as chemoattractants), which induces chemotactic behavior to guide nanomotors into tumors. Once in the tumors, the cationic F12+ is reduced to the diene F2 upon reaction with H2S, activating the nanomotor’s NIR fluorescence for real-time monitoring of drug delivery and release in vivo. Upon exposure to H2S, the nanomotor undergoes disassembly due to the disruption of electrostatic interactions between the anionic anticancer drugs and the cationic F12+, leading to the precise and controlled drug release, ensuring uniform distribution across the tumor. This innovative strategy would open avenues for delivering mRNA vaccines or other anionic drugs.","PeriodicalId":125,"journal":{"name":"Angewandte Chemie International Edition","volume":"39 1","pages":""},"PeriodicalIF":16.1000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angewandte Chemie International Edition","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1002/anie.202503297","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Nanomotors hold tremendous potential for drug delivery. However, current nanomotors face limitations that compromise efficiency of drug utilization, including the use of inorganic materials with suboptimal soft interface and biocompatibility, uncontrollable drug release, insufficient directional control and slow movement speeds. Herein, we present a novel near-infrared (NIR) light-driven porous unsymmetric nanomotor with ultrafast motion, which utilizes hydrogen sulfide (H2S)-responsive cationic organic π-electron structure-based electrochromic material (F12+) for the payload and controlled release of anionic anticancer drugs, enabling synergistic cancer chemotherapy and immunotherapy. We demonstrate that the nanomotor can precisely target tumors driven by thermophoresis, tumor-targeting peptide (RGD) and H2S (highly expressed in tumors and acted as chemoattractants), which induces chemotactic behavior to guide nanomotors into tumors. Once in the tumors, the cationic F12+ is reduced to the diene F2 upon reaction with H2S, activating the nanomotor’s NIR fluorescence for real-time monitoring of drug delivery and release in vivo. Upon exposure to H2S, the nanomotor undergoes disassembly due to the disruption of electrostatic interactions between the anionic anticancer drugs and the cationic F12+, leading to the precise and controlled drug release, ensuring uniform distribution across the tumor. This innovative strategy would open avenues for delivering mRNA vaccines or other anionic drugs.
基于光致电致变色材料的h2s控制药物释放纳米马达在协同肿瘤化疗免疫治疗中的应用。
纳米马达在药物输送方面具有巨大的潜力。然而,目前的纳米马达面临着影响药物利用效率的限制,包括使用软界面和生物相容性欠佳的无机材料,药物释放不可控,方向控制不足以及运动速度慢。在此,我们提出了一种新型的近红外(NIR)光驱动多孔非对称超快运动纳米马达,它利用硫化氢(H2S)响应的阳离子有机π-电子结构电致变色材料(F12+)作为负离子抗癌药物的有效载荷和控释,实现了癌症化疗和免疫治疗的协同作用。我们证明了纳米马达可以通过热泳、肿瘤靶向肽(RGD)和H2S(在肿瘤中高表达并作为趋化剂)驱动精确靶向肿瘤,诱导趋化行为引导纳米马达进入肿瘤。一旦进入肿瘤,阳离子F12+与H2S反应还原为二烯F2,激活纳米马达的近红外荧光,实时监测体内药物的传递和释放。当暴露于H2S时,由于阴离子抗癌药物与阳离子F12+之间的静电相互作用被破坏,纳米马达发生解体,导致药物精确和可控的释放,确保整个肿瘤均匀分布。这一创新策略将为mRNA疫苗或其他阴离子药物的输送开辟道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
26.60
自引率
6.60%
发文量
3549
审稿时长
1.5 months
期刊介绍: Angewandte Chemie, a journal of the German Chemical Society (GDCh), maintains a leading position among scholarly journals in general chemistry with an impressive Impact Factor of 16.6 (2022 Journal Citation Reports, Clarivate, 2023). Published weekly in a reader-friendly format, it features new articles almost every day. Established in 1887, Angewandte Chemie is a prominent chemistry journal, offering a dynamic blend of Review-type articles, Highlights, Communications, and Research Articles on a weekly basis, making it unique in the field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信